Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Growth deceleration in a girl treated with imatinib.

Literature DB >> 19152100

Growth deceleration in a girl treated with imatinib.

Tomiko Kimoto¹, Masami Inoue², Keisei Kawa².

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 2009 PMID： 19152100 DOI： 10.1007/s12185-008-0251-8

Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490

× No keyword cloud information.

4 in total

1. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.

Authors: Andrew Grey; Susannah O'Sullivan; Ian R Reid; Peter Browett
Journal: N Engl J Med Date: 2006-12-07 Impact factor: 91.245

2. Altered bone and mineral metabolism in patients receiving imatinib mesylate.

Authors: Ellin Berman; Maria Nicolaides; Robert G Maki; Martin Fleisher; Suzanne Chanel; Kelly Scheu; Bri-Anne Wilson; Glenn Heller; Nicholas P Sauter
Journal: N Engl J Med Date: 2006-05-11 Impact factor: 91.245

3. Imatinib as a potential antiresorptive therapy for bone disease.

Authors: Andrea L Dewar; Amanda N Farrugia; Mark R Condina; L Bik To; Timothy P Hughes; Barrie Vernon-Roberts; Andrew C W Zannettino
Journal: Blood Date: 2006-01-31 Impact factor: 22.113

4. Long-term imatinib therapy promotes bone formation in CML patients.

Authors: Stephen Fitter; Andrea L Dewar; Panagiota Kostakis; L Bik To; Timothy P Hughes; Marion M Roberts; Kevin Lynch; Barrie Vernon-Roberts; Andrew C W Zannettino
Journal: Blood Date: 2007-11-27 Impact factor: 22.113

4 in total

9 in total

1. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.

Authors: Nobuko Hijiya; Kirk R Schultz; Markus Metzler; Frederic Millot; Meinolf Suttorp
Journal: Blood Date: 2015-10-28 Impact factor: 22.113

Review 2. Management of chronic myeloid leukemia in childhood.

Authors: Meinolf Suttorp; Louise Eckardt; Josephine Tabea Tauer; Frederic Millot
Journal: Curr Hematol Malig Rep Date: 2012-06 Impact factor: 3.952

3. Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era.

Authors: Hideki Muramatsu; Yoshiyuki Takahashi; Hirotoshi Sakaguchi; Akira Shimada; Nobuhiro Nishio; Asahito Hama; Sayoko Doisaki; Hiroshi Yagasaki; Kimikazu Matsumoto; Koji Kato; Seiji Kojima
Journal: Int J Hematol Date: 2011-01-14 Impact factor: 2.490

9. Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth.

Authors: Josephine Tabea Tauer; Lorenz C Hofbauer; Rolang Jung; Reinhold G Erben; Meinolf Suttorp
Journal: Med Sci Monit Basic Res Date: 2013-11-04

9 in total

Growth deceleration in a girl treated with imatinib.

1. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.

2. Altered bone and mineral metabolism in patients receiving imatinib mesylate.

3. Imatinib as a potential antiresorptive therapy for bone disease.

4. Long-term imatinib therapy promotes bone formation in CML patients.

1. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.

Review 2. Management of chronic myeloid leukemia in childhood.

3. Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era.

Review 4. Endocrine side effects of broad-acting kinase inhibitors.

Review 5. Clinical review: kinase inhibitors: adverse effects related to the endocrine system.

6. The treatment of pediatric chronic myelogenous leukemia in the imatinib era.

7. The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation.

8. Childhood cancer incidence and survival in Japan and England: A population-based study (1993-2010).

9. Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth.